RAMO Bio-Med, Inc. Commences With Research on Charlottes Web or AC/DC Cultivation and Genetic Molecular Engineering
October 02 2014 - 11:59AM
InvestorsHub NewsWire
Las Vegas, NV - October 02, 2014 - InvestorsHub NewsWire -
RAMOIL MANAGEMENT, Ltd (OTC Pink:
RAMO) (PINKSHEETS:
RAMO), would like to announce that it has begun research on the
Charlottes Web or AC/DC cannabis strain, regarding cultivation and
genetic engineering or manipulation.
RAMO Bio-Med, Inc. has acquired and planted sufficient seedlings of
the strain AC/DC, a.k.a. Charlottes Web. Within 2 weeks, our
scientist will begin to genetically engineer these clones and
strain to increase the CBD % over 25% and reduce the THC % below
0.05% and ideally at or under 0.03% THC. Essentially, maximizing
the CBD percentage and minimizing the THC percentage of this strain
is our goal.
Finally, the RAMO Bio-Med in-house Scientists will increase the
AC/DC or Charlottes Web clones' yield potential more than 20%, to
maximize the plant production or yield (output).
Michael Goeree, Ramoil Management's Chairman, President and Chief
Executive Officer, said, "It took some time to secure proper
strains of AC/DC or Charlottes Web clones for research and genetic
engineering. This will become the basis of our CBD based Medicine
Production both here in America, as well as internationally."
Mr. Goeree further stated, "It is always a great day when the
cornerstone of any structure is secured and set into place."
About Ramoil Management, Ltd.
Ramoil Management, Ltd. (RAMO) is a development stage company. The
Company is an online wholesaler of E-cigarettes containing
nutraceutical vapor oils, E-cigarette delivery systems and
hydroponic lighting and nutrients.
About RAMO Bio-Med, Inc.
RAMO Bio-Med, Inc. is a wholly owned subsidiary of Ramoil
Management, Ltd. (RAMO) and is a development stage company. The
Company is the operating company of the newly acquired
"Supercritical CO2 Molecular Extraction Technology" and will be
building operating production facilities and research labs, both
domestically and internationally, focused on its own proprietary
strain of High CBD Extremely Low THC "Charlottes Webb" and
Extraction Facilities (Labs and Manufacturing), for the
development, production and sales of CBD extractions, concentrates
and medicines.
Forward Looking Statements:
This news release contains forward-looking statements made by
RAMOIL MANAGEMENT, LTD. All such statements included in this press
release, other than statements of historical fact, are
forward-looking statements. Although management believes that the
expectations reflected in such forward-looking statements are
reasonable, it can give no assurance that such expectations will
prove to have been correct. Actual results may differ materially
from those indicated by these statements. The following risk
factors, among others, could cause actual results to differ
materially from those described in any forward-looking statements.
These risks and uncertainties include, but are not limited to,
economic conditions, changes in the law or regulations, demand for
products of the Company, the effects of competition and other
factors that could cause actual results to differ materially from
those projected or represented in the forward looking statements.
Forward-looking statements are typically identified by the words:
believe, expect, anticipate, intend, estimate, and similar
expressions or which by their nature refer to future events. The
Company is not entitled to rely on the safe harbor provisions of
Section 27A of the Securities Act of 1933 and Section 21E of the
Securities Exchange Act of 1934 because it is not registered under
either Act.
CONTACT:
Company and Investor Relations Contact:
Frank Blainey, Esq.
+1-702-381-1961
Ramoilir@gmail.com
SOURCE Ramoil Management, Ltd.
Advantis (CE) (USOTC:ADVT)
Historical Stock Chart
From Aug 2024 to Sep 2024
Advantis (CE) (USOTC:ADVT)
Historical Stock Chart
From Sep 2023 to Sep 2024